Balaxi Pharmaceuticals Peer Comparison

NSE: BALAXI

₹22.73

₹-0.21 (-0.92%)

As on 24-Sep-2026IST

Market cap

₹125 Cr

Revenue (TTM)

₹280 Cr

P/E Ratio

51.8

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	125	37,212	27,783	26,915	27,712
Revenue (₹ Cr)	280	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	2.42	414.00	288.22	387.35	-371.81
Net Margin (%)	0.85	11.23	14.79	26.01	-3.93
RoE (%)	0.99	8.38	29.77	25.18	-3.85
Price to Earnings	51.77	90.98	96.40	69.69	--
Price-To-Book	0.50	7.39	20.70	15.60	3.46

Income Statement (₹ Cr)

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	280.11	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	283.72	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	271.07	2,792.00	1,485.56	919.25	8,195.15
EBITDA	9.04	772.00	450.24	542.56	1,010.13
Depreciation	2.54	226.00	50.83	37.68	857.51
EBIT	6.50	546.00	399.41	504.88	152.62
Interest	3.63	217.00	40.84	3.77	342.73
Other Income	3.61	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	6.48	463.00	371.35	528.56	-162.68
Provision for Tax	4.06	49.00	83.14	141.21	209.13
Profit after Tax	2.42	414.00	288.22	387.35	-371.81

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	249.08	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	25.80	1,712.00	202.03	42.40	5,044.14
Current Liabilities	62.16	1,622.00	835.87	230.82	4,758.28
Total Liabilities	337.03	8,578.00	2,326.71	1,983.96	17,723.32

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	81.68	5,343.00	519.60	1,026.85	10,211.52
Current Assets	251.43	2,606.00	1,681.81	881.27	7,191.66
Total Assets	337.03	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	55.79	2,125.00	259.37	26.49	5,495.48
Net Current Assets	189.27	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	768.26	19.09	17.25	95.72

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-4.50	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-20.78	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	0.44	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	-24.84	95.00	78.39	30.33	787.59

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	3.48	6.79	29.22	32.42	1.24
ROE (%)	0.99	8.38	29.77	25.18	-3.85
ROA (%)	0.75	4.94	24.77	21.93	-2.21
EBIT Margin (%)	2.32	15.32	20.63	34.54	1.66
Net Margin (%)	0.85	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-5.90	18.37	46.65	40.90	0.78
EBIT Growth (%)	-77.90	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-87.18	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-87.18	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	7.48	13.47	144.31	26.03	0.33

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	51.83	93.38	94.92	69.69	-88.56
Price / Book Value	0.50	7.39	20.70	15.60	3.46
Dividend Yield (%)	0.00	0.00	0.09	0.08	0.00
EV/EBITDA	18.44	50.10	61.51	49.24	31.53
Market Cap (₹ Cr)	86.51	19,071.62	12,753.19	20,944.75	18,108.89

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.09	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.13	0.09	0.05	0.02	0.09
Current Ratio	4.05	1.61	2.01	3.82	1.51
Quick Ratio	2.70	1.06	1.14	2.82	0.87
Interest Coverage	2.78	3.13	10.09	141.16	0.53

	Balaxi Pharmaceuticals	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	48.59	16.50	26.28	24.80	23.44
Asset Turnover	0.87	0.43	1.66	0.83	0.55
Receivable days	166.78	58.75	40.13	88.98	78.20
Inventory Days	109.40	75.82	60.29	56.04	93.30
Payable days	45.22	186.21	232.47	99.95	226.14
Cash Conversion Cycle	230.96	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.